Received Jan 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | UNK | UT8873MA | OT / RL |
patient receiving a different influenza vaccine (Fluzone NP) earlier than scheduled with no reported adverse event; Initial information received on 13-Jan-2026 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 22 months old male patient who receiving a different Influenza Usp Trival A-B Subvirion No Preservative Vaccine [Fluzone] earlier than scheduled with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 12-Jan-2026, the patient receiving (0.5ml, once) dose of suspect Influenza Usp Trival A-B Subvirion No Preservative Vaccine, Suspension for injection (strength: standard) (lot: UT8873MA, expiry date: 30-Jun-2026) via intramuscular route in the right vastus lateralis for influenza, earlier than scheduled with no reported adverse event (inappropriate schedule of product administration) (latency: same day). It was reported, The patient received a first dose of an influenza vaccine manufactured by GSK on 22DEC2026. The patient came in yesterday and received a dose of FLUZONE NP. The patient did not experience any adverse event. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.